

CLAIMS:

- 5 1. An isolated endostatin protein, wherein the protein has
an amino acid sequence selected from the group consisting of SEQ
ID NO:3 and SEQ ID NO:5.
- 10 2. The endostatin protein of Claim 1 having an amino
acid sequence of SEQ ID NO:3.
- 15 3. The endostatin protein of Claim 1 having an amino
acid sequence of SEQ ID NO:5.
- 20 4. The endostatin protein of Claim 1 made by a process
comprising, recombinantly producing the protein of Claim 1 in a
recombinant expression system, and isolating the recombinantly
produced protein in its un-refolded form.
- 25 5. The endostatin protein of Claim 4, wherein the
endostatin protein has an amino acid sequence of SEQ ID NO:3.
- 30 6. The endostatin protein of Claim 4, wherein the
endostatin protein has an amino acid sequence of SEQ ID NO:5.
- 25 7. The endostatin protein of Claim 4, wherein the
recombinant expression system is selected from the group
consisting of bacterial expression systems, yeast expression
systems and insect viral expression systems.
- 30 8. The endostatin protein of Claim 7, wherein the
recombinant expression system is *E. coli*, *Pichia*, or baculovirus.
- 35 9. An isolated nucleic acid molecule having a sequence
encoding an endostatin protein, wherein the nucleic acid sequence

20040311-00100

is selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.

5 10. The isolated nucleic acid molecule of Claim 9 having the sequence of SEQ ID NO:4.

11. The isolated nucleic acid molecule of Claim 9 having the sequence of SEQ ID NO:6.

10 12. The composition of Claim 6, further comprising, a vector containing the nucleic acid sequence encoding endostatin protein, wherein the vector is capable of expressing an endostatin protein when present in a cell.

15 13. The composition of Claim 9, wherein the nucleic acid has a sequence of SEQ ID NO:4.

20 14. The composition of Claim 9, wherein the nucleic acid has a sequence of SEQ ID NO:6.

25 15. The endostatin protein of Claim 1, further comprising a pharmaceutically acceptable excipient.

16. The endostatin protein of Claim 15, wherein the endostatin protein has a sequence of SEQ ID NO:3.

17. The endostatin protein of Claim 15, wherein the endostatin protein has a sequence of SEQ ID NO:5.

30 18. The composition of Claim 15, wherein the composition provides a sustained release of the endostatin protein for a period of at least 8 hours.

19. The endostatin protein of Claim 15, wherein the protein is administered to an individual for the treatment of an angiogenesis-related disease.

5 20. The endostatin protein of Claim 15, wherein the angiogenesis-related disease is an angiogenesis-dependent cancer.